BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 35082793)

  • 1. Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer.
    Lou S; Wang Y; Zhang J; Yin X; Zhang Y; Wang Y; Xue Y
    Front Immunol; 2021; 12():806324. PubMed ID: 35082793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between DNA damage repair gene somatic mutations and immune-related gene expression in ovarian cancer.
    Tian W; Shan B; Zhang Y; Ren Y; Liang S; Zhao J; Zhao Z; Wang G; Zhao X; Peng D; Bi R; Cai S; Bai Y; Wang H
    Cancer Med; 2020 Mar; 9(6):2190-2200. PubMed ID: 31991061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma.
    Zhou C; Lin A; Cao M; Ding W; Mou W; Guo N; Chen Z; Zhang J; Luo P
    Front Immunol; 2021; 12():634741. PubMed ID: 34220801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.
    Ronchetti L; Melucci E; De Nicola F; Goeman F; Casini B; Sperati F; Pallocca M; Terrenato I; Pizzuti L; Vici P; Sergi D; Di Lauro L; Amoreo CA; Gallo E; Diodoro MG; Pescarmona E; Vitale I; Barba M; Buglioni S; Mottolese M; Fanciulli M; De Maria R; Maugeri-Saccà M
    Int J Cancer; 2017 Jun; 140(11):2587-2595. PubMed ID: 28233295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diverse immune response of DNA damage repair-deficient tumors.
    Qing T; Jun T; Lindblad KE; Lujambio A; Marczyk M; Pusztai L; Huang KL
    Cell Rep Med; 2021 May; 2(5):100276. PubMed ID: 34095878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
    Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
    BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.
    Ged Y; Chaim JL; DiNatale RG; Knezevic A; Kotecha RR; Carlo MI; Lee CH; Foster A; Feldman DR; Teo MY; Iyer G; Chan T; Patil S; Motzer RJ; Hakimi AA; Voss MH
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32571992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer.
    Dai J; Jiang M; He K; Wang H; Chen P; Guo H; Zhao W; Lu H; He Y; Zhou C
    Front Oncol; 2021; 11():708294. PubMed ID: 34604048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel DNA damage repair-related gene signature predicting survival, immune infiltration and drug sensitivity in cervical cancer based on single cell sequencing.
    Xiang X; Kang J; Jiang J; Zhang Y; Zhang Y; Li L; Peng X
    Front Immunol; 2023; 14():1198391. PubMed ID: 37449209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer.
    Cheng Y; Bu D; Zhang Q; Sun R; Lyle S; Zhao G; Dong L; Li H; Zhao Y; Yu J; Hao X
    J Adv Res; 2023 Sep; 51():121-134. PubMed ID: 36351537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA damage response alterations in clear cell renal cell carcinoma: clinical, molecular, and prognostic implications.
    Jing X; Qin X; Liu H; Liu H; Wang H; Qin J; Zhang Y; Cao S; Fan X
    Eur J Med Res; 2024 Feb; 29(1):107. PubMed ID: 38326910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Characterization of RNA Processing Factors in Gastric Cancer Identifies a Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses.
    Lou S; Meng F; Yin X; Zhang Y; Han B; Xue Y
    Front Immunol; 2021; 12():719628. PubMed ID: 34413861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulated Wnt1-inducible signaling pathway protein 1 correlates with poor prognosis and drug resistance by reducing DNA repair in gastric cancer.
    Zhang LH; Wang Y; Fan QQ; Liu YK; Li LH; Qi XW; Mao Y; Hua D
    World J Gastroenterol; 2019 Oct; 25(38):5814-5825. PubMed ID: 31636474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature.
    Zhang C; Li D; Yu R; Li C; Song Y; Chen X; Fan Y; Liu Y; Qu X
    Front Immunol; 2021; 12():651033. PubMed ID: 34054812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA damage signalling as an anti-cancer barrier in gastric intestinal metaplasia.
    Krishnan V; Lim DXE; Hoang PM; Srivastava S; Matsuo J; Huang KK; Zhu F; Ho KY; So JBY; Khor C; Tsao S; Teh M; Fock KM; Ang TL; Jeyasekharan AD; Tan P; Yeoh KG; Ito Y
    Gut; 2020 Oct; 69(10):1738-1749. PubMed ID: 31937549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer.
    Ding K; He Y; Wei J; Fu S; Wang J; Chen Z; Zhang H; Qu Y; Liang K; Gong X; Qiu L; Chen D; Xiao B; Du H
    Front Immunol; 2022; 13():943090. PubMed ID: 36081518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic Profiling of Lower-Grade Gliomas Subtype with Distinct Molecular and Clinicopathologic Characteristics via Altered DNA-Damage Repair Features.
    Maimaiti A; Liu Y; Abulaiti A; Wang X; Feng Z; Wang J; Mijiti M; Turhon M; Alimu N; Wang Y; Liang W; Jiang L; Pei Y
    J Mol Neurosci; 2023 May; 73(4-5):269-286. PubMed ID: 37067735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical prognostication and immunotherapy response prediction in esophageal squamous cell carcinoma using the DNA damage repair-associated signature.
    Zhang P; Wen B; Gong J; Liu Z; Zhang M; Zhou G; Zhang L; Zhang Z
    Environ Toxicol; 2024 May; 39(5):2803-2816. PubMed ID: 38287713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.